Design-in before StemSight's clinical process is locked
StemSight is developing iPSC-derived corneal cells with clinical trials targeted around 2027; media choice now will be locked into its regulated process. A collaboration to qualify Defined Bioscience media for its differentiation protocol could create a long-term clinical customer and generate comparative data.
Evidence from the records
- “Fully defined media formulations with stabilized growth factors, reducing the cost and variability of stem cell culture.”
- “Corneal cells derived from induced pluripotent stem cells (iPS); clinical trials targeted around 2027.”
- If it works
- A clinical-stage reference customer and recurring media volume through trials.
- First step
- Offer StemSight free evaluation kits of HiDef-B8 with a joint comparison protocol.
